Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.

Dumont AG, Dumont SN, Trent JC.

Chin J Cancer. 2012 Jul;31(7):327-34. doi: 10.5732/cjc.012.10032. Epub 2012 May 24. Review.

PMID:
22640628
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?

Glück S, Yip AY, Ng EL.

Expert Opin Ther Targets. 2012 Mar;16 Suppl 1:S17-22. doi: 10.1517/14728222.2012.655725. Epub 2012 Feb 8.

PMID:
22316427
[PubMed - indexed for MEDLINE]
3.

Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB.

Mol Cancer Ther. 2012 Mar;11(3):582-93. doi: 10.1158/1535-7163.MCT-11-0820. Epub 2012 Jan 16.

PMID:
22248472
[PubMed - indexed for MEDLINE]
Free Article
4.

Phase II trial of temsirolimus in patients with metastatic breast cancer.

Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ.

Breast Cancer Res Treat. 2012 Nov;136(2):355-63. doi: 10.1007/s10549-011-1910-7. Epub 2012 Jan 13.

PMID:
22245973
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients.

Doi T, Takiuchi H, Ohtsu A, Fuse N, Goto M, Yoshida M, Dote N, Kuze Y, Jinno F, Fujimoto M, Takubo T, Nakayama N, Tsutsumi R.

Br J Cancer. 2012 Feb 14;106(4):666-72. doi: 10.1038/bjc.2011.590. Epub 2012 Jan 12.

PMID:
22240796
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Targeting the PI3K signaling pathway in cancer therapy.

Bartholomeusz C, Gonzalez-Angulo AM.

Expert Opin Ther Targets. 2012 Jan;16(1):121-30. doi: 10.1517/14728222.2011.644788. Epub 2012 Jan 12. Review.

PMID:
22239433
[PubMed - indexed for MEDLINE]
7.

The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology.

Pollak M.

Clin Cancer Res. 2012 Jan 1;18(1):40-50. doi: 10.1158/1078-0432.CCR-11-0998.

PMID:
22215905
[PubMed - indexed for MEDLINE]
Free Article
8.

Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology.

Gao J, Chang YS, Jallal B, Viner J.

Cancer Res. 2012 Jan 1;72(1):3-12. doi: 10.1158/0008-5472.CAN-11-0550. Review.

PMID:
22215692
[PubMed - indexed for MEDLINE]
Free Article
9.

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.

Stopfer P, Marzin K, Narjes H, Gansser D, Shahidi M, Uttereuther-Fischer M, Ebner T.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1051-61. doi: 10.1007/s00280-011-1803-9. Epub 2011 Dec 27.

PMID:
22200729
[PubMed - indexed for MEDLINE]
10.

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN.

N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.

PMID:
22149876
[PubMed - indexed for MEDLINE]
Free Article
11.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group.

N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.

PMID:
22149875
[PubMed - indexed for MEDLINE]
Free Article
12.

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.

Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Ladror US, Xu AJ, Iyer R, Harlan JE, Solomon LR, Donawho CK, Penning TD, Johnson EF, Shoemaker AR.

Clin Cancer Res. 2012 Jan 15;18(2):510-23. doi: 10.1158/1078-0432.CCR-11-1973. Epub 2011 Nov 29.

PMID:
22128301
[PubMed - indexed for MEDLINE]
Free Article
13.

Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

Saini KS, Azim HA Jr, Metzger-Filho O, Loi S, Sotiriou C, de Azambuja E, Piccart M.

Breast. 2011 Oct;20 Suppl 3:S20-7. doi: 10.1016/S0960-9776(11)70289-2. Review.

PMID:
22015288
[PubMed - indexed for MEDLINE]
14.

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

Miller TW, Balko JM, Arteaga CL.

J Clin Oncol. 2011 Nov 20;29(33):4452-61. doi: 10.1200/JCO.2010.34.4879. Epub 2011 Oct 17. Review.

PMID:
22010023
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.

LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX.

Clin Cancer Res. 2011 Oct 15;17(20):6437-47. doi: 10.1158/1078-0432.CCR-11-0762. Review.

PMID:
22003071
[PubMed - indexed for MEDLINE]
Free Article
16.

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review.

Mathew J, Perez EA.

Curr Opin Oncol. 2011 Nov;23(6):594-600. doi: 10.1097/CCO.0b013e32834b895c. Review.

PMID:
21986845
[PubMed - indexed for MEDLINE]
17.

Dual HER2-targeted approaches in HER2-positive breast cancer.

Ahn ER, Vogel CL.

Breast Cancer Res Treat. 2012 Jan;131(2):371-83. doi: 10.1007/s10549-011-1781-y. Epub 2011 Sep 29. Review.

PMID:
21956210
[PubMed - indexed for MEDLINE]
18.

Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.

Gupta M, Lorusso PM, Wang B, Yi JH, Burris HA 3rd, Beeram M, Modi S, Chu YW, Agresta S, Klencke B, Joshi A, Girish S.

J Clin Pharmacol. 2012 May;52(5):691-703. doi: 10.1177/0091270011403742. Epub 2011 Sep 27.

PMID:
21953571
[PubMed - indexed for MEDLINE]
19.

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A.

Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.

PMID:
21862407
[PubMed - indexed for MEDLINE]
20.

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH.

Cancer Res. 2011 Sep 1;71(17):5626-34. doi: 10.1158/0008-5472.CAN-11-1227. Epub 2011 Jul 27.

PMID:
21795476
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk